capecitabine has been researched along with Experimental Mammary Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, HW; Li, L; Li, XQ; Shao, RG; Zhang, H; Zhang, SH; Zhang, YP | 1 |
| Angelini, PD; Arribas, J; Aura, C; Baselga, J; Cameron, D; Chandarlapaty, S; Ellis, C; Gagnon, R; Geyer, C; Gomez, H; Guzman, M; Jimenez, J; Koehler, M; Parra, JL; Prudkin, L; Rosen, N; Sánchez, G; Scaltriti, M | 1 |
| Conn, CE; Danon, SJ; Drummond, CJ; Gong, X; Moghaddam, MJ; Sagnella, SM; Waddington, LJ | 1 |
| Fujimoto-Ouchi, K; Hata, K; Hiraga, T; Ikeda, F; Kitagaki, J; Tanaka, Y; Yoneda, T | 1 |
| Cao, D; Pizzorno, G; Wan, L; Yan, R; Zeng, J | 1 |
| Endo, M; Fukase, Y; Ishikawa, T; Ishitsuka, H; Sawada, N; Shinbori, N; Tanaka, Y | 1 |
6 other study(ies) available for capecitabine and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Lidamycin up-regulates the expression of thymidine phosphorylase and enhances the effects of capecitabine on the growth and pulmonary metastases of murine breast carcinoma.
Topics: Aminoglycosides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Enediynes; Enzyme Induction; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Up-Regulation | 2013 |
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Lamellar crystalline self-assembly behaviour and solid lipid nanoparticles of a palmityl prodrug analogue of Capecitabine--a chemotherapy agent.
Topics: Animals; Calorimetry, Differential Scanning; Capecitabine; Cell Line; Cell Line, Tumor; Cell Proliferation; Colloids; Cryoelectron Microscopy; Deoxycytidine; Female; Fluorouracil; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Molecular Structure; Nanoparticles; Particle Size; Prodrugs; Scattering, Small Angle; Thermogravimetry; Transition Temperature; Tumor Burden; Water; X-Ray Diffraction | 2011 |
Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Luciferases; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Time Factors; Transfection; Treatment Outcome | 2005 |
Modulation of uridine phosphorylase gene expression by tumor necrosis factor-alpha enhances the antiproliferative activity of the capecitabine intermediate 5'-deoxy-5-fluorouridine in breast cancer cells.
Topics: Animals; Base Sequence; Capecitabine; Deoxycytidine; DNA Primers; Drug Synergism; Electrophoretic Mobility Shift Assay; Floxuridine; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Mammary Neoplasms, Experimental; Mice; NF-kappa B; Tumor Necrosis Factor-alpha; Uridine Phosphorylase | 2006 |
Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Floxuridine; Fluorouracil; Humans; Kinetics; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Transplantation; Thymidine Phosphorylase; Time Factors; Up-Regulation | 1999 |